AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED NEW AUTHORIZATIONS TO RESUME PATIENT ENROLLMENT IN ITS PHASE 3 STUDIES…